Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMPUAOE)

Drug Name

SCH-527123 Drug Info

Synonyms

Navarixin; 473727-83-2; Sch527123; SCH 527123; (R)-2-Hydroxy-N,N-dimethyl-3-((2-((1-(5-methylfuran-2-yl)propyl)amino)-3,4-dioxocyclobut-1-en-1-yl)amino)benzamide; MK-7123; CHEMBL216981; (R)-2-hydroxy-N,N-dimethyl-3-(2-(1-(5-methylfuran-2-yl)propylamino)-3,4-dioxocyclobut-1-enylamino)benzamide; SCHEMBL184744; GTPL8497; KS-00001CQK; CTK8B8735; MolPort-023-331-228; BDBM50200880; MK7123; ANW-61143; ZINC100033051; AKOS016003539; CS-0609; NCGC00390675-01; HY-10198; AX8217127; TC-149888; W-5650; SCH 527123,CAS:473727-83-2; PF-00547659

Indication

Disease Entry	ICD 11	Status	REF
Chronic obstructive pulmonary disease	CA22	Phase 2	[1]
Inflammatory bowel disease	DD72	Phase 2	[2]
Ulcerative colitis	DD71	Phase 2	[2]
Solid tumour/cancer	2A00-2F9Z	Phase 1	[3]

Cross-matching ID

PubChem CID: 9865554
TTD Drug ID: DMPUAOE

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting C-X-C chemokine receptor type 1 (CXCR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[5]
Reparixin	DMVBA7I	Pancreatic islet transplantation failure	NE84	Phase 3	[5]
SX-682	DMHMG6X	Melanoma	2C30	Phase 1	[6]
INDOPROFEN	DM5QSKN	Gout	FA25	Withdrawn from market	[5]
R-ketoprofen	DMHSUQ1	N. A.	N. A.	Discontinued in Phase 2	[5]
2-(3-Isopropyl-phenyl)-propionic acid	DMUOWNE	Discovery agent	N.A.	Investigative	[5]
2-[3-(1-Phenyl-ethyl)-phenyl]-propionic acid	DMWIUR0	Discovery agent	N.A.	Investigative	[5]
(R)-2-(4-Isobutyl-phenyl)-propionamide	DMBQ0PR	Discovery agent	N.A.	Investigative	[5]
(R)-N-Hydroxy-2-(4-isobutyl-phenyl)-propionamide	DMWRIQG	Discovery agent	N.A.	Investigative	[5]
2-[3-(2-Methyl-butyl)-phenyl]-propionic acid	DMKSDT4	Discovery agent	N.A.	Investigative	[5]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Mucosal addressin cell adhesion molecule 1 (MADCAM1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
SHP647	DMEWRXA	Ulcerative colitis	DD71	Phase 3	[7]
------------------------------------------------------------------------------------

Drug(s) Targeting C-X-C chemokine receptor type 2 (CXCR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[5]
Clotrimazole	DMMFCIH	Cutaneous candidiasis	1F23.14	Approved	[8]
Reparixin	DMVBA7I	Pancreatic islet transplantation failure	NE84	Phase 3	[5]
SB-265610	DM8TKG5	Asthma	CA23	Phase 2	[9]
AZD-5069	DM3JSFK	Asthma	CA23	Phase 2	[10]
PS-938285	DMHZIFJ	Chronic obstructive pulmonary disease	CA22	Phase 2	[11]
GSK1325756	DMA6RBF	Chronic obstructive pulmonary disease	CA22	Phase 2	[12]
SB-656933	DMCY785	Chronic obstructive pulmonary disease	CA22	Phase 2	[13]
RIST4721	DMA3DKO	Hidradenitis suppurativa	ED92.0	Phase 2	[14]
SX-682	DMHMG6X	Melanoma	2C30	Phase 1	[6]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
C-X-C chemokine receptor type 1 (CXCR1)	TTMWT8Z	CXCR1_HUMAN	Antagonist	[3]
C-X-C chemokine receptor type 2 (CXCR2)	TT30C9G	CXCR2_HUMAN	Modulator	[4]
Mucosal addressin cell adhesion molecule 1 (MADCAM1)	TTBD6I7	MADCA_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8497).
2	Emerging drugs to treat Crohn's disease. Expert Opin Emerg Drugs. 2007 Mar;12(1):49-59.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	CXCR2 Antagonist MK-7123.A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease.Am J Respir Crit Care Med.2015 May 1;191(9):1001-11.
5	2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31.
6	Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models. Clin Cancer Res. 2020 Mar 15;26(6):1420-1431.
7	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8	Mode of action of clotrimazole: implications for therapy. Am J Obstet Gynecol. 1985 Aug 1;152(7 Pt 2):939-44.
9	Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
10	Pharmacological characterization of AZD5069, a slowly reversible CXC chemokine receptor 2 antagonist. J Pharmacol Exp Ther. 2015 May;353(2):340-50.
11	CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008.
12	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
13	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
14	A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar Pustulosis. Dermatol Ther (Heidelb). 2021 Dec;11(6):2179-2193.